Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational autologous biologic therapy, developed by Clinique Juge, consists of intra-articular injections combining autologous microfat with platelet-rich plasma (PRP). Evaluated in the MICROPREP clinical trial (NCT04352075), the treatment utilizes the patient's own processed adipose tissue, which contains stromal vascular fraction cells and mesenchymal stem cells, alongside concentrated platelets and growth factors from PRP. The microfat acts as a biological scaffold or matrix to contain the PRP and potentiate its trophic effects on injured cartilage, aiming to reduce symptoms and delay the need for knee arthroplasty in patients with knee osteoarthritis resistant to medical treatment. It is classified as an Advanced Therapy Medicinal Product (ATMP).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous microfat + platelet-rich plasma.